Litigation Details for ACADIA Pharmaceuticals Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

« Back to Dashboard

ACADIA Pharmaceuticals Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

Docket		Date Filed	2022-10-21
Court	District Court, D. Delaware	Date Terminated
Cause	35:271 Patent Infringement	Assigned To	Gregory B. Williams
Jury Demand	None	Referred To
Patents	10,646,480; 10,849,891; 11,452,721
Link to Docket	External link to docket

Details for ACADIA Pharmaceuticals Inc. v. MSN Laboratories Private Limited (D. Del. 2022)

Date Filed	Document No.	Description	Snippet	Link To Document
2022-10-21				External link to document

ACADIA Pharmaceuticals v. MSN Laboratories Patent Litigation: Case No. 1:22-cv-01388

Last updated: October 30, 2026

ACADIA Pharmaceuticals Inc. sued MSN Laboratories Private Limited in the U.S. District Court for the District of Delaware after MSN filed an abbreviated new drug application seeking approval to market generic pimavanserin, the active pharmaceutical ingredient in Nuplazid. The case concerned patents covering the use of pimavanserin for hallucinations and delusions associated with Parkinson's disease psychosis.

The litigation was a Hatch-Waxman Paragraph IV action. The public docket reflects resolution through settlement rather than a trial or final judicial determination on patent validity or infringement. The settlement terms, including any authorized generic launch date, were not publicly disclosed in the court docket.

What drug and indication were at issue in ACADIA v. MSN?

The dispute involved Nuplazid, marketed by ACADIA under the generic name pimavanserin tartrate.

Item	Information
Brand	Nuplazid
Active ingredient	Pimavanserin tartrate
Dosage form	Oral dosage forms, including 34 mg capsules
FDA-approved indication	Treatment of hallucinations and delusions associated with Parkinson's disease psychosis
NDA holder	ACADIA Pharmaceuticals Inc.
Regulatory pathway challenged	ANDA under Section 505(j) of the Federal Food, Drug, and Cosmetic Act
Court	U.S. District Court for the District of Delaware
Case number	1:22-cv-01388
Nature of action	Hatch-Waxman patent infringement action
Defendant	MSN Laboratories Private Limited

FDA approved Nuplazid in 2016 for Parkinson's disease psychosis. Unlike many antipsychotic products, pimavanserin was approved without a schizophrenia indication and was developed to address psychosis symptoms associated with Parkinson's disease without directly blocking dopamine D2 receptors (U.S. Food and Drug Administration, 2016).

What patents did ACADIA assert against MSN Laboratories?

ACADIA's case was directed principally to later-issued method-of-use patents covering pimavanserin treatment for Parkinson's disease psychosis. The asserted patent family included U.S. Patent No. 10,849,919 and U.S. Patent No. 11,452,688.

Patent	General subject matter	Reported expiration framework
U.S. Patent No. 10,849,919	Methods of treating hallucinations and delusions associated with Parkinson's disease psychosis	March 2038, before any applicable patent-term adjustment or extension
U.S. Patent No. 11,452,688	Continuation patent directed to related pimavanserin treatment methods	March 2038, before any applicable patent-term adjustment or extension

The patents are method-of-use patents rather than composition-of-matter patents covering pimavanserin itself. That distinction matters. A generic applicant can sometimes design around a method patent by limiting labeling, distribution, or marketing to nonprotected indications. The risk is higher when the patented indication is the principal or only commercially meaningful use of the reference product.

The Orange Book status of a listed patent, rather than the patent's existence alone, is critical in an ANDA dispute. An Orange Book-listed patent requires the applicant to certify under Section 505(j)(2)(A)(vii). A Paragraph IV certification alleges that the listed patent is invalid, unenforceable, or will not be infringed.

When did ACADIA file the lawsuit against MSN?

ACADIA filed the complaint in the District of Delaware in 2022 after receiving MSN's Paragraph IV notice concerning its ANDA for generic pimavanserin. The action was assigned case number 1:22-cv-01388.

The filing of a Paragraph IV suit within 45 days of receiving the notice generally triggers a 30-month stay of FDA approval under the Hatch-Waxman framework, unless the stay is shortened or otherwise terminated. The stay prevents FDA approval of the challenged ANDA while the litigation proceeds, subject to statutory exceptions and court action.

ACADIA filed related patent cases against other generic applicants, including Aurobindo and Zydus. The parallel cases reflected a broader challenge to the Nuplazid patent estate rather than a dispute unique to MSN.

What were MSN's likely Paragraph IV positions?

The public litigation structure indicates that MSN challenged the asserted patents through Paragraph IV certifications. The principal defenses in this type of case are:

1. Noninfringement, based on the proposed generic label or the product's intended use.
2. Invalidity for lack of patentable subject matter, anticipation, obviousness, inadequate written description, or lack of enablement.
3. Unenforceability, potentially based on inequitable conduct or other misconduct before the U.S. Patent and Trademark Office.
4. Regulatory arguments concerning the scope of the reference product's approved labeling and the applicant's proposed labeling.

The public docket does not show a final merits ruling resolving those defenses. The parties ended the case through settlement, so the court did not issue a final judgment holding the asserted patents valid and infringed.

What was the litigation timeline?

Date	Event
2022	MSN submitted an ANDA seeking approval for generic pimavanserin and delivered a Paragraph IV notice to ACADIA.
2022	ACADIA filed Case No. 1:22-cv-01388 in the District of Delaware.
2022-2023	The parties litigated claim construction, infringement, invalidity, and regulatory issues under the Hatch-Waxman framework.
2023 or later	The case was resolved by agreement between ACADIA and MSN.
After settlement	The action was dismissed pursuant to the parties' settlement, without a public merits judgment.

The precise settlement date and operative commercial terms should be read from the final docket dismissal and any publicly filed settlement-related documents. Hatch-Waxman settlements often remain partly confidential.

What is the Orange Book status of Nuplazid?

The relevant Nuplazid patent protection was based on method-of-use listings rather than a remaining basic compound patent. The key commercial protection extended into 2038 through later patents directed to treating Parkinson's disease psychosis with pimavanserin.

This structure creates two distinct forms of exclusivity:

Regulatory exclusivity

Nuplazid's original FDA approval generated regulatory exclusivity periods that protected the application from certain competing approvals. Those periods are separate from patent protection and do not determine the ultimate generic entry date once the relevant patents remain enforceable.

Patent exclusivity

The asserted patents extended beyond the original approval-era exclusivity period. A successful Paragraph IV challenge could have enabled earlier approval and launch. A settlement could instead establish a negotiated launch date, license terms, or other restrictions.

The public case record does not disclose a judicial finding that the patents were invalid or unenforceable. It also does not publicly establish an unrestricted MSN launch before the asserted patent expiration dates.

How strong was ACADIA's patent estate?

ACADIA's position was materially stronger than it would have been with only an expired composition patent or a single narrow formulation patent. The estate included later method-of-use patents that directly mapped onto the principal approved use of Nuplazid.

Strengths

The estate had several commercial advantages:

• The patents covered the disease indication driving Nuplazid sales.
• The patent terms extended to approximately 2038.
• The patents were issued and listed in the Orange Book.
• A generic applicant faced potential infringement exposure if its labeling encouraged the patented use.
• Multiple patents and related cases increased the cost and complexity of an early launch challenge.

Vulnerabilities

The estate also had litigation risks:

• Method-of-use claims can be challenged through label-scraping or carve-out strategies.
• Generic applicants can argue that treatment of Parkinson's disease psychosis was obvious based on prior clinical and pharmacological evidence.
• Indication patents do not necessarily prevent all off-label use after generic entry.
• Claim scope and induced-infringement theories depend heavily on the proposed label, promotional conduct, and distribution practices.
• Settlement pressure increases when the commercial value of the product depends on one primary indication.

The absence of a final merits decision means the case cannot be scored as a judicial validation of ACADIA's patent claims.

Did the case involve formulation patents?

The central dispute was not publicly characterized as a formulation-patent case. It focused on method-of-use protection for pimavanserin in Parkinson's disease psychosis.

That distinction affects generic-entry analysis. Formulation patents can block a specific dosage form, release profile, excipient system, or manufacturing process while leaving alternative formulations available. A method-of-use patent instead targets the therapeutic use. MSN's ability to enter would therefore depend on the scope of its proposed label and whether the label would induce infringement of the asserted treatment claims.

There is no public indication that the case produced a final ruling concerning a novel formulation, controlled-release technology, particle-size limitation, or manufacturing process.

What was the litigation outcome?

The case ended without a reported trial verdict or final validity decision. The docket reflects dismissal pursuant to settlement.

A settlement in this setting normally resolves:

• The patent infringement claims;
• MSN's Paragraph IV challenge;
• The risk of an at-risk generic launch;
• The parties' obligations concerning FDA approval and commercialization;
• The possibility of future litigation over the same ANDA.

The specific settlement economics were not disclosed publicly. The available record does not establish whether MSN received a license, an agreed launch date, supply rights, or another form of consideration.

The lack of public settlement terms prevents a definitive calculation of MSN's commercial entry date. It also prevents a finding that ACADIA obtained a particular period of guaranteed market exclusivity from MSN.

Which companies challenged the Nuplazid patent estate?

ACADIA brought related litigation against multiple generic applicants. Publicly identified defendants included MSN Laboratories, Aurobindo Pharma, and Zydus Pharmaceuticals.

Company	Litigation significance
MSN Laboratories	Defendant in Case No. 1:22-cv-01388
Aurobindo Pharma	Defendant in a related Nuplazid Paragraph IV action
Zydus Pharmaceuticals	Defendant in a related Nuplazid Paragraph IV action

The existence of multiple ANDA challenges increased the risk that a favorable settlement with one applicant would not eliminate all generic-entry exposure. ACADIA therefore had an incentive to coordinate settlements and preserve the enforceability of the broader patent estate.

What generic entry risks existed for Nuplazid?

The principal risk was an at-risk launch following a successful Paragraph IV challenge. Such a launch could have exposed the generic applicant to damages and injunctive relief, but it could also have accelerated competition before patent expiry.

The main entry scenarios were:

Scenario	Effect on ACADIA
ACADIA wins after trial	Generic approval remains blocked until patent expiry or settlement-based license date
Generic wins on invalidity	Early FDA approval and potential immediate launch
Generic wins on noninfringement	Launch risk depends on labeling and remaining patents
Settlement with delayed launch	Predictable erosion date with reduced trial risk
Settlement with licensed launch	Competition begins on negotiated terms
Settlement with no public launch terms	Commercial exposure cannot be quantified from the docket alone

Because the asserted patents extended to approximately 2038, an invalidity or noninfringement judgment would have had substantial value to MSN. For ACADIA, settlement protected against the possibility of a loss that could have materially accelerated generic competition.

How did the case affect ACADIA's revenue exposure?

Nuplazid was ACADIA's principal commercial product before the company's broader commercial expansion. The product generated hundreds of millions of dollars in annual revenue, making generic-entry timing a material valuation issue.

A negotiated launch after the mid-2030s would preserve most of the remaining patent-backed revenue opportunity. An early launch following a successful Paragraph IV challenge could have caused:

• Rapid price erosion;
• Loss of pharmacy and payer leverage;
• Reduced prescriptions;
• Lower royalty or milestone value in commercial transactions;
• Increased pressure on ACADIA's pipeline to replace Nuplazid revenue.

The financial impact of this particular settlement cannot be quantified without the confidential launch date and economic terms. ACADIA's public filings identify Nuplazid patent litigation as a material business risk but do not provide a case-specific valuation of the MSN settlement.

What is the current legal significance of ACADIA v. MSN?

The case is most significant as a resolved Hatch-Waxman challenge to ACADIA's late-expiring method-of-use patents. It did not establish a reported precedent on pimavanserin patent validity, induced infringement, skinny-label strategy, or the enforceability of the asserted claims.

For competitive analysis, the case supports four conclusions:

1. ACADIA maintained meaningful patent protection beyond the original Nuplazid approval exclusivity period.
2. MSN challenged that protection through the Paragraph IV pathway.
3. The litigation ended by settlement rather than an adjudicated loss for either side.
4. Generic-entry timing depends on the confidential settlement terms and the status of other ANDA challengers.

Key Takeaways

• ACADIA sued MSN Laboratories in the District of Delaware under Case No. 1:22-cv-01388.
• The dispute concerned generic pimavanserin and Nuplazid's Parkinson's disease psychosis indication.
• The asserted protection centered on method-of-use patents, including U.S. Patent Nos. 10,849,919 and 11,452,688.
• The relevant patent term extended to approximately March 2038, before any applicable term adjustment or extension.
• MSN's ANDA included a Paragraph IV challenge.
• The case was dismissed following settlement and did not produce a final ruling on validity or infringement.
• The settlement terms and any authorized generic launch date were not publicly disclosed.
• The case reduced ACADIA's immediate litigation risk but did not, by itself, eliminate all generic-entry risk from other applicants.

FAQs About ACADIA Pharmaceuticals v. MSN Laboratories

What was MSN Laboratories trying to market?

MSN sought FDA approval for a generic version of pimavanserin, the active ingredient in Nuplazid, for the treatment of Parkinson's disease psychosis.

Was U.S. Patent No. 10,849,919 invalidated?

No. The case ended through settlement, and the public docket does not show a final judgment invalidating the patent.

Did MSN receive permission to launch before 2038?

The public record does not disclose the settlement's commercial terms or establish a specific MSN launch date.

Was the dispute about pimavanserin's chemical composition?

The principal dispute concerned method-of-use protection for treating Parkinson's disease psychosis, not a basic composition-of-matter patent.

Does the settlement prevent all generic pimavanserin competition?

No. The case resolved ACADIA's dispute with MSN. Other ANDA applicants and other patents can create separate generic-entry risks.

References

Acadia Pharmaceuticals Inc. v. MSN Laboratories Private Limited, No. 1:22-cv-01388, U.S. District Court for the District of Delaware, docket materials.

Acadia Pharmaceuticals Inc. (2024). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934.

U.S. Food and Drug Administration. (2016). FDA approves new drug to treat hallucinations and delusions associated with Parkinson's disease. FDA News Release.

U.S. Patent and Trademark Office. (2021). U.S. Patent No. 10,849,919: Methods of treating hallucinations and delusions associated with Parkinson's disease psychosis.

U.S. Patent and Trademark Office. (2022). U.S. Patent No. 11,452,688: Methods of treating hallucinations and delusions associated with Parkinson's disease psychosis.

U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.